Study of a new immune cell treatment for blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment called iMagic for people with blood cancers like non-Hodgkin lymphoma or multiple myeloma that have come back or stopped responding to standard treatment. The goal is to see if it is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with non-Hodgkin lymphoma or multiple myeloma that came back or didn't respond to treatment.
- You are able to take care of yourself (fully active or only limited in heavy physical work).
- You are expected to live at least 3 months.
- You do not have a serious active infection, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This study tests an investigational injection called WGb-0302 for people with multiple myeloma that has come back or not responded to standard treatments. The goal is to see if it is safe and helpful, possibly by targeting a protein on the cancer cells called BCMA.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
Hear when a new Relapsed/Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.